c-erbB-2 gene detection (c-erbB-2, neu, HER-2)

The c-erbB-2 gene, also known as the neu or HER-2 gene, is a cell-proto-oncogene that overexpresses and amplifies its oncogene and its protein product (P185) in a variety of tumors. The pathological study of c-erbB-2 oncoprotein product P185 is first seen in breast cancer, and its role is also clear. It is generally believed that the positive expression of c-erbB-2 protein product can be used as an independent indicator to judge the prognosis of breast cancer. Basic Information Specialist Category: Oncology Inspection Category: Genetic Testing (DNA) Applicable gender: whether men and women apply fasting: fasting Analysis results: Below normal: Normal value: no Above normal: negative: Normally negative, no expression or low expression. Positive: Positive expression can be found in various cancers, such as breast cancer, ovarian cancer, gastric cancer, esophageal cancer, salivary gland tumor, lung cancer, cholangiocarcinoma, bladder cancer, prostate cancer, colorectal cancer and the like. Positive people also indicated that there is the possibility of multi-drug resistance, which has guiding significance for clinical medication. Tips: Strictly avoid contamination of specimens during testing. Normal value No expression or low expression. Clinical significance Clinically adapted to the research and evaluation of various types of tumors. Its positive expression can be found in various cancers, such as breast cancer, ovarian cancer, gastric cancer, esophageal cancer, parotid gland tumor, lung cancer, cholangiocarcinoma, bladder cancer, prostate cancer, colorectal cancer and the like. Positive people also indicated that there is the possibility of multi-drug resistance, which has guiding significance for clinical medication. Positive results may be diseases: breast cancer, inflammatory breast cancer, ovarian cancer, stomach cancer, menopausal breast cancer 1, no absolute or relative contraindications. 2. Strictly avoid contamination of specimens during the testing process. Inspection process There are two most commonly used methods: immunohistochemistry (IHC) and in situ hybridization (fluorescence probe method FISH, chromogen probe method CISH). Immunohistochemistry is a method for detecting the expression of c-erbB-2 encoded protein in cancer cells embedded in paraffin-embedded tissues. It is a qualitative or semi-quantitative assay. Currently, the IHC kit approved by the FDA has been adopted. The results are less sensitive, correct, and reliable than FISH or CISH. The IHC method is often used as a preliminary screening for determining the expression of c-erbB-2 in breast cancer tissues. It is simple, economical, and strongly positive (+ ++) The positive coincidence rate between the expression and the in situ hybridization method is about 90%, and the consistency between the two is up to 98%. The moderate (++) expression is only about 17% when tested by in situ hybridization. Gene amplification, weak positive (+) or negative (-) expression were also consistent with the results of in situ hybridization. In situ hybridization (FISH or CISH) is required to confirm the c-erbB-2 amplification of cancer tissues before the selection of the bio-targeted therapeutic drug Herceptin. Of course, IHC and FISH are applicable to c- The determination of erbB-2 expression can more accurately guide clinical practice. Not suitable for the crowd Those who do not have an indication for examination should not be examined. Adverse reactions and risks 1. Infection: Pay attention to aseptic operation when collecting blood, avoid contamination of water and other parts at the blood collection site to avoid local infection. 2, bleeding: after the blood is given a full compression time, especially coagulopathy, bleeding tendency, to avoid local subcutaneous oozing, bruising and swelling.